Literature DB >> 34037961

Antiphospholipid antibodies in patients with Graves' orbitopathy: preliminary data.

Mirjana B Bećarević1, Marija Sarić Matutinović2, Miloš Žarković3, Biljana Nedeljković Beleslin3, Jasmina Ćirić3, Svetlana D Ignjatović2.   

Abstract

PURPOSE: Graves' orbitopathy (GO) is an inflammatory autoimmune disorder of the orbit and while the antiphospholipid antibodies (aPL) Abs were associated with the markers of inflammation in the antiphospholipid syndrome (APS), there is no literature that investigate the presence of aPL Abs in GO. We analyzed the prevalence of aPL Abs and the differences between aPL (+) and aPL (-) subgroups of GO patients.
METHODS: Study included consecutive patients with GO (66 with Graves' (GD), 10 with Hashimoto (HD), and 8 were euthyroid). Anticardiolipin (aCL) and anti-beta 2glycoprotein I (aβ2gpI) Abs were measured by ELISA.
RESULTS: aPL Abs were present in 9/84 (10.71%) patients. The IgM aβ2gpI Abs were present in 8/66 and in 1/10 patients with GD and HD. The IgG aCL Abs were present in one GD patient, and IgM aCL were present in 3/66 GD and in 1/10 patients with HD. In GD group, anti-Tg Abs were in positive correlation with aβ2gpI IgG (p = 0.000) and with anti-TPO Abs (p = 0.016). In HD group, anti-Tg Abs were in positive correlation with IgM aCL (p = 0.042), while anti-TPO Abs were in positive correlation with aβ2gpI IgM (p = 0.014).
CONCLUSION: This study is the first report of the aPL Abs presence in GO patients. The anti-thyroid Abs were linked to aPL suggesting that their presence is not the sole consequence of hyperstimulation of autoreactive B-lymphocytes. Larger studies are necessary to confirm potential cause-effect relations.

Entities:  

Keywords:  Antiphospholipid antibodies; Apolipoproteins; Autoimmune thyroid diseases; Graves’ orbitopathy; Interleukine 6

Year:  2021        PMID: 34037961     DOI: 10.1007/s12020-021-02769-z

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  6 in total

Review 1.  Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers.

Authors:  W M Wiersinga; P Perros; G J Kahaly; M P Mourits; L Baldeschi; K Boboridis; A Boschi; A J Dickinson; P Kendall-Taylor; G E Krassas; C M Lane; J H Lazarus; C Marcocci; M Marino; M Nardi; C Neoh; J Orgiazzi; A Pinchera; S Pitz; M F Prummel; M S Sartini; M Stahl; G von Arx
Journal:  Eur J Endocrinol       Date:  2006-09       Impact factor: 6.664

2.  Double positivity of the IgG isotype of both anticardiolipin and anti-β2gpI antibodies is associated with the highest number of vascular impairment parameters in patients with primary antiphospholipid syndrome: preliminary data.

Authors:  Mirjana Bećarević; Duško Mirković; Svetlana Ignjatović
Journal:  Clin Rheumatol       Date:  2016-10-14       Impact factor: 2.980

Review 3.  Management of Graves' ophthalmopathy: reality and perspectives.

Authors:  L Bartalena; A Pinchera; C Marcocci
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

4.  A Retrospective Study on the Association between Thyroid Autoantibodies with β2-glycoprotein and Cardiolipin Antibodies in Recurrent Miscarriage.

Authors:  Regina Promberger; Katharina Walch; Rudolf Seemann; Sophie Pils; Johannes Ott
Journal:  Iran J Allergy Asthma Immunol       Date:  2017-02       Impact factor: 1.464

5.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.

Authors:  Luigi Bartalena; Lelio Baldeschi; Kostas Boboridis; Anja Eckstein; George J Kahaly; Claudio Marcocci; Petros Perros; Mario Salvi; Wilmar M Wiersinga
Journal:  Eur Thyroid J       Date:  2016-03-02

6.  Presence of systemic autoimmune disorders in patients with autoimmune thyroid diseases.

Authors:  M G Tektonidou; M Anapliotou; P Vlachoyiannopoulos; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.